
|Videos|July 12, 2016 (Updated: April 18, 2020)
- Gastrointestinal Cancers: mCRC (Issue 9)
- Volume 1
- Issue 9
Impact of HER2 Amplification in Colorectal Cancer
Kanwal Raghav,MBBS, MD, Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, the University of Texas M.D. Anderson Cancer Center, discusses HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer.
Kanwal Raghav,MBBS, MD, Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, the University of Texas M.D. Anderson Cancer Center, discusses HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer.
Articles in this issue
over 9 years ago
Role of DPR in Colorectal Cancerover 9 years ago
Overview of the Lume 1 and 2 Trialsover 9 years ago
Novel Immunotherapy Combinations on Horizon for mCRCRelated Content
Advertisement



mFOLFOX/Bevacizumab/Atezolizumab Improves PFS in dMMR/MSI-H Colorectal Cancer
Published: | Updated:





























